Previous 10 | Next 10 |
SeaChange International Inc. (SEAC) is expected to report for quarter end 2023-10-31 Helen of Troy Limited (HELE) is expected to report $2.46 for Q3 2024 Commercial Metals Company (CMC) is expected to report $1.43 for Q1 2024 Pure Cycle Corporation (PCYO) is expected to report for Q1 ...
VANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, interim Chief...
2023-11-21 09:22:34 ET More on CytoDyn Financial information for CytoDyn For further details see: CytoDyn appoints Lalezari as its interim CEO
VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Jacob Lalezari as ...
VANCOUVER, Washington, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Dear Shareholders, We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of the Company. Throughout our history, CytoDyn has made great st...
Equity Bancshares Inc. Class A (EQBK) is expected to report $0.75 for Q3 2023 Silvergate Capital Corporation Class A (SICP) is expected to report for Q3 2023 Bellway plc ADR (BLWYY) is expected to report for Q4 2023 Fulton Financial Corporation (FULT) is expected to report $0.4 for Q3...
North Dallas Bank & Trust Co. (NODB) is expected to report for Q3 2023 Neogen Corporation (NEOG) is expected to report $0.14 for Q1 2024 E2open Parent Holdings Inc.Class A (ETWO) is expected to report $0.04 for Q2 2024 TSR Inc. (TSRI) is expected to report for Q1 2024 Solitron...
Cytodyn Inc (CYDY) is expected to report for quarter end 2023-08-31
Claim Filed in Former CRO Litigation for Damages Exceeding $100M Dr. Arman Returns from Medical Leave as SVP of Business Operations Webcast to be held Monday, July 24 th , 2023, at 1 PM PT / 4 PM ET VANCOUVER, Washington, July 11, 2023 (GLOBE NEWSWIRE) -- Cyt...
2023-05-24 17:16:00 ET Cyrus Arman, CytoDyn ( OTCQB:CYDY ) president, has taken a medical leave of absence. CFO Antonio Migliarese will assume Arman's responsibilities while he is out. Migliarese will be assisted by interim CMO Melissa Palmer and Salah Kivlighn, ...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...
VANCOUVER, Washington, May 16, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, I write today to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), as we approach the end of our 2024 fiscal year (May 31, 2024), and to sincerely thank you for your unwavering...